Zobrazeno 1 - 10 of 157 pro vyhledávání: '"Bohannan Z"'
1
Akademický článek
Predicting likelihood of in vivo chemotherapy response in canine lymphoma using ex vivo drug sensitivity and immunophenotyping data in a machine learning model.
Autor: Bohannan Z; ImpriMed, Inc., Palo Alto, California, USA., Pudupakam RS; ImpriMed, Inc., Palo Alto, California, USA., Koo J; ImpriMed, Inc., Palo Alto, California, USA.; ImpriMed Korea, Inc., Seoul, Republic of Korea.; Department of Chemical Engineering, Hongik University, Seoul, Republic of Korea., Horwitz H; ImpriMed, Inc., Palo Alto, California, USA., Tsang J; ImpriMed, Inc., Palo Alto, California, USA., Polley A; ImpriMed, Inc., Palo Alto, California, USA., Han EJ; ImpriMed, Inc., Palo Alto, California, USA., Fernandez E; ImpriMed, Inc., Palo Alto, California, USA., Park S; ImpriMed, Inc., Palo Alto, California, USA., Swartzfager D; ImpriMed, Inc., Palo Alto, California, USA., Qi NSX; ImpriMed, Inc., Palo Alto, California, USA., Tu C; SAGE Veterinary Centers, Dublin, California, USA., Rankin WV; SAGE Veterinary Centers, Dublin, California, USA., Thamm DH; Flint Animal Cancer Center, Colorado State University, Fort Collins, Colorado, USA., Lee HR; ImpriMed, Inc., Palo Alto, California, USA.; ImpriMed Korea, Inc., Seoul, Republic of Korea., Lim S; ImpriMed, Inc., Palo Alto, California, USA.; ImpriMed Korea, Inc., Seoul, Republic of Korea.
Publikováno v: Veterinary and comparative oncology [Vet Comp Oncol] 2021 Mar; Vol. 19 (1), pp. 160-171. Date of Electronic Publication: 2020 Oct 20.
Zobrazit plný text záznamu
2
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
3
Akademický článek
Investigating protein patterns in human leukemia cell line experiments: A Bayesian approach for extremely small sample sizes.
Autor: Chekouo T; Department of Mathematics and Statistics, University of Calgary, Calgary, Canada., Stingo FC; Department of Statistics, Computer Science, Applications 'G. Parenti', University of Florence, Florence, Italy., Class CA; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Yan Y; Department of Neurosurgery, The University of Texas Health Science Center at Houston, Houston, TX, USA., Bohannan Z; Division of Research, The University of Houston, Houston, TX, USA., Wei Y; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Garcia-Manero G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Hanash S; Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Do KA; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Publikováno v: Statistical methods in medical research [Stat Methods Med Res] 2020 Apr; Vol. 29 (4), pp. 1181-1196. Date of Electronic Publication: 2019 Jun 07.
Zobrazit plný text záznamu
4
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
5
Akademický článek
Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher-risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents.
Autor: Jabbour E; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Faderl S; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Sasaki K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Kadia T; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Daver N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Pemmaraju N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Patel K; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Khoury JD; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Bueso-Ramos C; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Bohannan Z; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Ravandi F; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Borthakur G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Verstovsek S; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Miller D; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Maduike R; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Hosing C; Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, Texas., Kantarjian HM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Garcia-Manero G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Publikováno v: Cancer [Cancer] 2017 Feb 15; Vol. 123 (4), pp. 629-637. Date of Electronic Publication: 2016 Oct 14.
Zobrazit plný text záznamu
6
Akademický článek
Down-regulation of EZH2 expression in myelodysplastic syndromes.
Autor: Cabrero M; Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States. Electronic address: ggarciam@mdanderson.org., Wei Y; Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States., Yang H; Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States., Ganan-Gomez I; Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States., Bohannan Z; Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States., Colla S; Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States., Marchesini M; Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States., Bravo GM; Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States., Takahashi K; Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States., Bueso-Ramos C; Departments of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States., Garcia-Manero G; Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.
Publikováno v: Leukemia research [Leuk Res] 2016 May; Vol. 44, pp. 1-7. Date of Electronic Publication: 2016 Feb 26.
Zobrazit plný text záznamu
7
Editorial & Opinion
Downregulation of Protection of Telomeres 1 expression in myelodysplastic syndromes with 7q deletion.
Autor: Cabrero M; Departments of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Yu Y; Albert Einstein College of Medicine, Bronx, NY, USA., Verma A; Albert Einstein College of Medicine, Bronx, NY, USA., Yang H; Departments of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Colla S; Departments of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Jia Y; Departments of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Zheng H; Departments of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Bohannan Z; Departments of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ganan-Gomez I; Departments of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Futreal A; Departments of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Takahashi K; Departments of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Chin L; Departments of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kantarjian H; Departments of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Pellagatti A; Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, Oxford, UK., Bowman T; Albert Einstein College of Medicine, Bronx, NY, USA., Boultwood J; Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, Oxford, UK., Garcia-Manero G; Departments of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wei Y; Departments of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA. ywei@mdanderson.org.
Publikováno v: British journal of haematology [Br J Haematol] 2016 Apr; Vol. 173 (1), pp. 161-5. Date of Electronic Publication: 2015 Jun 24.
Zobrazit plný text záznamu
8
Akademický článek
Clofarabine Preconditioning followed by Allogeneic Transplant Using TBI and Post-Transplant Cyclophosphamide for Relapsed Refractory Leukemia.
Autor: Naik, Seema1 (AUTHOR) krakszawski@pennstatehealth.psu.edu, Rakszawski, Kevin1 (AUTHOR), Zheng, Hong1 (AUTHOR), Claxton, David1 (AUTHOR), Minagawa, Kentaro1 (AUTHOR), Mineishi, Shin1 (AUTHOR)
Publikováno v: International Journal of Molecular Sciences. Jan2024, Vol. 25 Issue 2, p957. 9p.
Zobrazit plný text záznamu
9
Akademický článek
Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes.
Autor: Badar T; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Patel KP; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Thompson PA; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., DiNardo C; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Takahashi K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Cabrero M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Borthakur G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Cortes J; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Konopleva M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kadia T; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Bohannan Z; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Pierce S; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Jabbour EJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ravandi F; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Daver N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Luthra R; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kantarjian H; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Garcia-Manero G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: ggarciam@mdanderson.org.
Publikováno v: Leukemia research [Leuk Res] 2015 Dec; Vol. 39 (12), pp. 1367-74. Date of Electronic Publication: 2015 Oct 19.
Zobrazit plný text záznamu
10
Akademický článek
Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study.
Autor: Jabbour E; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: ejabbour@mdanderson.org., Kantarjian H; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ravandi F; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Thomas D; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Huang X; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Faderl S; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Pemmaraju N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Daver N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Garcia-Manero G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Sasaki K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Cortes J; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Garris R; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Yin CC; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Khoury JD; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Jorgensen J; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Estrov Z; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Bohannan Z; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Konopleva M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kadia T; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Jain N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., DiNardo C; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wierda W; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Jeanis V; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., O'Brien S; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Publikováno v: The Lancet. Oncology [Lancet Oncol] 2015 Nov; Vol. 16 (15), pp. 1547-1555. Date of Electronic Publication: 2015 Sep 30.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje